Aquestive Therapeutics (AQST) Accumulated Expenses (2017 - 2026)

Aquestive Therapeutics' Accumulated Expenses history runs 10 years deep, the most recent figure standing at $3.4 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 4.07% year-over-year to $3.4 million in Q1 2026; TTM through Mar 2026 was $3.4 million, a 4.07% increase from a year earlier, with the FY2025 full-year figure at $5.0 million, down 14.86% from the prior year.
• Accumulated Expenses retreated to $3.4 million in Q1 2026 per AQST's latest filing, from $5.0 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $8.0 million in Q4 2022 and bottomed at $3.3 million in Q1 2025.
• The 5-year median for Accumulated Expenses is $5.0 million (2025), against an average of $5.4 million.
• Across the five-year window, Accumulated Expenses sank 39.46% in 2023 and soared 33.1% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $8.0 million in 2022, then retreated by 18.45% to $6.5 million in 2023, then retreated by 9.08% to $5.9 million in 2024, then retreated by 14.86% to $5.0 million in 2025, then plunged by 31.42% to $3.4 million in 2026.
• Per Business Quant, the three latest AQST Accumulated Expenses figures stand at $3.4 million (Q1 2026), $5.0 million (Q4 2025), and $5.1 million (Q3 2025).